RC
GILD icon

Rexford Capital’s Gilead Sciences GILD Stock Holding History

Rexford Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$820K Buy
6,492
+40
+0.6% +$5.27K 0.5% 56
2026
Q1 		$899K Buy
6,452
+103
+2% +$14.4K 0.64% 48
2025
Q4 		$779K Hold
6,349
– – 0.59% 51
2025
Q3 		$705K Buy
6,349
+70
+1% +$7.96K 0.55% 54
2025
Q2 		$696K Buy
+6,279
New +$668K 0.58% 54

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rexford Capital's GILD Position: Q2 2026 in Review

Rexford Capital increased its Gilead Sciences (GILD) stake by 0.62% in Q2 2026, buying an estimated $5.27K and bringing the position to 6,492 shares worth $820K. The position accounts for 0.5% of the portfolio, ranked #56.

Rexford Capital first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $899K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Rexford Capital held 6,492 shares of Gilead Sciences worth $820K as of Q2 2026.
  • Rexford Capital bought 40 Gilead Sciences shares in Q2 2026, an estimated $5.27K.
  • Gilead Sciences made up 0.5% of Rexford Capital's portfolio in Q2 2026, its #56 holding.
  • Rexford Capital first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • Rexford Capital's Gilead Sciences position peaked at $899K in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Rexford Capital's 13F filing for Q2 2026, filed 29 Jul 2026.